Lifetime treatment costs of β-thalassaemia major

Clinical and Laboratory Haematology

Volumn 21, Issue 6, 1999, Pages 377-385

  Karnon, J ^a   Zeuner, D ^b   Brown, J ^a   Ades, A E ^b   Wonke, B ^c   Modell, B ^d  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c WHITTINGTON HOSPITAL   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cost model; Lifetime treatment; Thalassaemia

Indexed keywords

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CHILD; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; GENETIC DISORDER; HUMAN; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RESOURCE ALLOCATION; SURVIVAL RATE; TREATMENT PLANNING;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; DRUG THERAPY; HEALTH CARE COSTS; HUMANS; INFANT; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 0033373889     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.1999.00262.x     Document Type: Article

References (37)

1. Anapliotou M.L., Kastanias I.T., Psara P., Evangelou E., Liparaki M. & Dimitriou P. (1995) The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clinical Endocrinology 42, 179-187.
2. Bagni B., DeSanctis V., Bagni I. et al. (1997) Osteopenia in thalassaemic patients with primary and secondary amenorrhea. In: Ando S. & Brancati C., eds. Endocrine Disorders in Thalassaemia, Physiopathological and Therapeutic Aspects, pp. 53-58. New York, Springer Verlag.
3. Blumhardt L.D. & Wood C. (1996) The economics of multiple sclerosis: a cost of illness study. British Journal of Medical Economics 10, 99-118.
4. Borgna Pignatti C., Zurlo M.G., De Stefano P. et al. (1993) Outcome of thalassaemia treated with conventional therapy. Bone Marrow Transplant 12 (Suppl. 1), 2-4.
5. Brecht J.G., Poldrugo F. & Schadlich P.K. (1996) Alcoholism: the cost of illness in the Federal Republic of Germany. Pharmacoeconomics 10, 484-493.
6. Brittenham G.M., Griffith P.M., Nienhuis A.W. et al. (1994) Efficacy of desferrioxamine in preventing complications of iron overload in patients with thalassaemia major. New England Journal of Medicine 331, 567-573.
7. Bronspiegel Weintrob N., Olivieri N.F., Tyler B., Andrews D.F., Freedman M.H. & Holland F.J. (1990) Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassaemia major. New England Journal of Medicine 323, 713-719.
8. Cao A., Gabutti V., Galanello R. et al. (1997) Management Protocol for the Treatment of Thalassaemia Patients. Thalassaemia International Federation. Cyprus, 1-49.
9. Cao A., Galanello R., Rosatelli M.C., Argiolu F. & De Virgiliis S. (1996) Clinical experience of management of thalassaemia: the Sardinian experience. Seminars in Hematology 33, 66-75.
10. Davics S.C. & Wonke B. (1991) The management of haemoglobinopathies. Baillieres Clinical Haematology 4, 361-389.
11. De Sanctis V., Katz M., Vullo C., Bagni B., Ughi M. & Wonke B. (1994) Effect of different treatment regimens on linear growth and final height in beta-thalassaemia major. Clinical Endocrinology 40, 791-798.
12. Drummond M.F., O'Brien B., Stoddart G.L. & Torrance G.W. (1997) Methods for the Economic Evaluation of Health Care Programmes, 2nd edn, Oxford Medical Publications, Oxford, 68-74.
13. Gerard K., Donaldson C. & Maynard A.K. (1989) The cost of diabetes. Diabetic Medicine 6, 164-170.
14. Giardina P.J. & Grady R.W. (1995) Chelation therapy in beta-thalassaemia: the benefits and limitations of desferrioxamine. Seminars in Hematology 32, 304-312.
15. Giardina P.J., Schnider R., Lesser M.L. et al. (1997) Abnormal bone metabolism in thalassaemia. In: Ando S. & Brancati C., eds. Endocrine Disorders in Thalassaemia, Physiopathological and Therapeutic Aspects, pp. 39-46. Springer Verlag, New York.
16. Gold M.R., Siegel J.E., Russell L.B. & Weinstein M.C. (1996) Cost-Effectiveness in Health and Medicine. Oxford University Press, Oxford.
17. Goni M.H., Markussis V. & Tolis G. (1997) Bone mineral content by single and dual photon absorptiometry in thalassaemia patients. In: Ando S. & Brancati C., eds. Endocrine Disorders in Thalassaemia, Physiopathological and Therapeutic Aspects, Springer Verlag. New York, 47-52.
18. Italian Working Group on Endocrine Complications in Thalassaemia major (1995) Multicentre study on prevalence of endocrine complications in thalassaemia major. Clinical Endocrinology 42, 581-586.
19. Jensen C.E., Tuck S.M. & Wonke B. (1995) Fertility in beta thalassaemia major: a report of 16 pregnancies, preconceptual evaluation and a review of the literature. British Journal of Obstetrics and Gynaecology 102, 625-629.
20. Karnon J.D., Brown J., Zeuner D. & Briggs A. (1997) Issues in the economic evaluation of antenatal screening programmes for genetic disorders. HERG Discussion Paper. Brunel University, Uxbridge.
21. Maetzel A. (1997) Cost of illness and the burden of disease. Journal of Rheumatology 24, 3-5.
22. Malone D.C., Lawson K.A., Smith D.H., Arrighi H.M. & Battista C. (1997) A. cost of illness study of allergic rhinitis in the United States. Journal of Allergy and Clinical Immunology 99, 22-27.
23. Meadows A.T., Bunin N.J., Leahey A.M. & Wheeler D.S. (1994) Bone marrow transplantation: what parents should know. The Children's Hospital of Philadelphia, Armour Pharmaceutical Company, (http://oncolink. upenn.edu/specialty/chemo/bmt/ bmtparent.html).
24. Netten A. & Dennett J. (1996) Unit costs of health and social care. The University of Kent, Personal Social Services Research Unit, pp. 1-147.
25. Olivieri N.F., Nathan D.G., MacMillan J.H. et al. (1994) Survival in medically treated patients with homozygous beta-thalassaemia. New England Journal of Medicine 331, 574-578.
26. Parmley W.W. (1996) Cost-effective management of heart failure. Clinical Cardiology 19, 240-242. © 1999 Blackwell Science Ltd. Clin. Lab. Haem., 21, 377-385
27. Provan D. (1999) Better blood transfusion. British Medical Journal 318, 1435-1436.
28. Ratip S. & Modell B. (1996) Psychological and sociological aspects of the thalassaemias. Seminars in Hematology 33, 53-65.
29. Rebulla P. & Modell B. (1991) Transfusion requirements and effects in patients with thalassaemia major. Cooleycare programme, Lancet 337, 277-280.
30. Richardson M.E., Matthews R.N., Alison J.F. et al. (1993) Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major. Australian and New Zealand Journal of Medicine 23, 656-661.
31. Savona Ventura C. & Bonello F. (1994) Beta-thalassaemia syndromes and pregnancy. Obstetric and Gynecological Survey 49, 129-137.
32. Tymstra T. (1991) Prenatal diagnosis, prenatal screening and the rise of the tentative pregnancy. International Journal of Technology Assessment in Health Care 7, 509-516.
33. WHO Working Group on Haemoglobinopathies (1994) Guidelines for the Control of Haemoglobin disorders. World Health Organisation, Geneva, 3-57.
34. Williams R. (1994) Diabetes mellitus. In: Stevens A. & Raftery J., eds. Health Care Needs Assessment: the Epidemiologically Based Needs Assessment Reviews, pp. 31-57. Radcliffe Medical Press, Oxford.
35. Wonke B., Hoffbrand A.V. & Aldouri M.A. (1989) Cardiac complications in homozygous beta-thalassaemia. In: Buckner C.D., Gayle R.P. & Lucarelli G. eds. Advances and Controversies in Thalassaemia Therapy. Bone Marrow Transplantation and Other Approaches. Alan R. Liss, Inc, New York, 51-56.
36. Zeuner D., Ades A., Karnon J., Brown J., Dezateux C. & Anionwu E. (1999) Screening for haemoglobinopathies in the UK: Review and economic analysis. NHS Health Technology Assessment Programme 3, 1-186.
37. Zurlo M.G., De Stefano P., Borgna Pignatti C. et al. (1989) Survival and causes of death in thalassaemia major. Lancet 8653, 27-30.